Aerie Pharmaceuticals Inc

NASDAQ:AERI  
13.26
-0.07 (-0.52%)
Products, Regulatory

Aerie Pharma Announces Positive Phase 3 Results For Netarsudil Ophthalmic Solution 0.02%

Published: 10/12/2021 10:41 GMT
Aerie Pharmaceuticals Inc (AERI) - Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan.
Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan.
Aerie Pharmaceuticals Inc - in Netarsudil Ophthalmic Solution Phase 3 Clinical Trial Medications Were Safe and Well-tolerated.
Aerie - in Trial, at Week 4, Mean Diurnal Iop Was Statistically Significantly Lower in Netarsudil 0.02% Group Compared to Ripasudil 0.4% Group.
Aerie Pharmaceuticals Inc - Findings Also Suggest That Iop Reduction May Predict Strong Efficacy in Normal Or Low-tension Glaucoma Patients.